Blood Tests Could Predict Muscle Loss and Physical Decline in Older Adults

As populations age globally, sarcopenia—the progressive loss of muscle mass, strength, and physical performance—has become a major health concern affecting up to 13% of older adults by 2045. Current diagnosis relies on expensive, time-consuming methods like body scans and physical tests that may miss early-stage disease. This study investigated whether simple blood tests could provide an alternative approach for monitoring muscle health in aging.

Researchers analyzed plasma biomarkers in 93 older adults (average age 74, 88% female) from a hospital-based cohort, measuring muscle mass, grip strength, and physical performance at baseline and after two years. They focused on biomarkers recommended by European osteoporosis experts, including hormones, inflammatory markers, and muscle-specific proteins.

The results revealed distinct biomarker patterns for different aspects of sarcopenia. Leptin, typically associated with appetite regulation, showed strong negative correlations with muscle mass both cross-sectionally and longitudinally, suggesting it could predict muscle loss over time. DHEAS, an anabolic hormone, positively correlated with muscle mass and physical performance, while inflammatory markers IL-6 and GDF-15 were linked to poorer physical function. Interestingly, participants showed significant declines in walking speed and overall physical performance over two years, even without measurable muscle mass loss.

These findings have important clinical implications. Blood biomarkers could enable earlier detection of sarcopenia risk, allowing for timely interventions like exercise programs or nutritional support before functional decline becomes severe. The ability to monitor progression through routine blood tests could also help clinicians adjust treatment strategies and track intervention effectiveness more efficiently than current methods.

However, the study has limitations including a small, predominantly female sample from a single hospital, which may limit generalizability. The cohort also focused on individuals with osteoporosis, potentially affecting biomarker patterns. Larger, more diverse studies are needed to validate these biomarkers across different populations and establish clinical cutoff values for practical use.